期刊文献+

硼替佐米联合地塞米松治疗多发性骨髓瘤的疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨硼替佐米联合地塞米松治疗多发性骨髓瘤的临床疗效。方法本文按照随机数字表法将41例多发性骨髓瘤患者随机分为观察组和对照组,其中观察组患者采用硼替佐米联合地塞米松治疗,而对照组则采用传统治疗措施,比较2组的临床疗效和不良反应。结果观察组的总反应率明显高于对照组(χ2=7.38,P<0.05)。结论硼替佐米联合地塞米松治疗多发性骨髓瘤其疗效显著,不良反应较轻,且有部分逆转肾功能不全的作用,具有较好的耐受性,改善患者的预后,值得临床推广应用。
作者 金鑫
出处 《中外医疗》 2012年第9期100-100,共1页 China & Foreign Medical Treatment
  • 相关文献

参考文献4

二级参考文献37

  • 1Kyle RA,Leong T,Li S, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer,2006, 106 : 1958-1966.
  • 2Sundar J, Brian G, Jeffrey W, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol, 2005,129: 776- 783.
  • 3Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol, 1999,105:127-130.
  • 4Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 1998,102: 1115- 1123.
  • 5Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 2003, 348: 1875-1883.
  • 6OShea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplanta- tion: a single-centre experience in 211 patients. Bone Marrow Transplant, 2006,37:731-737.
  • 7Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Resuits of an IFM phase II study. Haematologica, 2006,1:1498- 1505.
  • 8San Miguel JF, Blade Creixenti J, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica, 1999,84 : 36-58.
  • 9Sirohi B, Powles R, Kulkarni S, et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001. 28 :29- 37.
  • 10Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Hematol, 2000. 65 : 175-181.

共引文献28

同被引文献26

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部